Navigation Links
Albemarle Enters Ibuprofen Agreement with Dr. Reddy's
Date:7/8/2008

Indian company to purchase, distribute US-made bulk API

BATON ROUGE, La., July 8 /PRNewswire-FirstCall/ -- Specialty chemicals maker Albemarle Corporation (NYSE: ALB), a leading global manufacturer of the anti-inflammatory agent ibuprofen and other active pharmaceutical ingredients (APIs), has signed a global agreement with pharmaceutical company Dr. Reddy's Laboratories Ltd. As per the agreement, effective immediately, Albemarle has appointed Dr. Reddy's as a non-exclusive distributor of Albemarle's bulk ibuprofen API. As part of the agreement, Dr. Reddy's will market, sell and distribute Albemarle's ibuprofen API to Dr. Reddy's global client base. In addition, Albemarle will also supply Dr. Reddy's a substantial quantity of its ibuprofen API requirements for use in the company's generic ibuprofen tablets.

(Logo: http://www.newscom.com/cgi-bin/prnh/20050801/ALBEMARLELOGO )

"Albemarle has been manufacturing ibuprofen for more than 25 years with a record of high quality, and the proven capacity to accommodate our significant volumes. We are confident that by working with Albemarle, we will be able to address our global ibuprofen requirements," said Patrick Glaser, Vice President of Dr. Reddy's North America Generics business.

"We are pleased to supply Dr. Reddy's with the volume and quality of ibuprofen they need to continue their efforts in the global prescription generic market," said Dave Clary, Vice President of Albemarle's Fine Chemistry Services (FCS) division, which manufactures ibuprofen in the company's FDA- inspected facility in Orangeburg, S.C. "We are also delighted to add them as a distributor for our bulk ibuprofen product. Dr. Reddy's is a growing player in the world pharmaceutical industry, and we look forward to working with them in the coming years."

Albemarle's FCS division makes and markets bulk and niche APIs for over- the-counter and prescription drugs, and provides custom manufacturing, R&D and other services to makers of pharmaceuticals, agricultural chemicals, specialty polymers and other high-value industry sectors. The FCS division is part of the company's Fine Chemicals business segment.

Dr. Reddy's Laboratories conducts research in the areas of diabetes, obesity, cardiovascular diseases, anti-infectives, and inflammation. The India-based company produces finished dosage forms, APIs, and biotechnology products, which are marketed globally, with a focus on India, the United States, Europe, and Russia. Learn more about Dr Reddy's Labs at http://www.drreddys.com.

Albemarle Corporation, headquartered in Baton Rouge, Louisiana, is a leading global developer, manufacturer and marketer of highly engineered specialty chemicals for consumer electronics; petroleum and petrochemical processing; transportation and industrial products; pharmaceuticals; agricultural products; and construction and packaging materials. The Company operates in three business segments-Polymer Additives, Catalysts and Fine Chemicals, and serves customers in approximately 100 countries. Learn more about Albemarle at http://www.albemarle.com.

"Safe Harbor" Statement under the Private Securities Litigation Reform Act of 1995: Statements in this press release regarding Albemarle Corporation's business which are not historical facts are "forward-looking statements" that involve risks and uncertainties. For a discussion of such risks and uncertainties, which could cause actual results to differ from those contained in the forward-looking statements, see "Risk Factors" in the Company's Annual Report on Form 10-K.


'/>"/>
SOURCE Albemarle Corporation
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Cepheid Enters Into Five-Year Agreement With Northrop Grumman for the Purchase of Anthrax Test Cartridges for Use in United States Postal Service Biohazard Detection Systems
2. Human Pheromone Sciences Enters Into Agreement to Reposition and Promote its Natural Attraction(R) Brand
3. Isis Enters Broad Collaboration With Ortho-McNeil, Inc. for the Discovery, Development and Commercialization of Antisense Drugs to Treat Metabolic Diseases
4. Carrington Subsidiary DelSite Biotechnologies Enters into Technology Evaluation Rights License Agreement for Transdermal Delivery of Vaccines
5. Cepheid Enters Agreement To Exclusively License HPV Portfolio Developed by Quantovir AB
6. GeneGo Enters Multi-Year Agreement With Bristol Myers Squibb for Access to GeneGo Software Suite and Databases
7. Keryx Biopharmaceuticals, Inc. Enters into Licensing Agreement with Japan Tobacco and Torii Pharmaceutical for Development and Commercialization of Hyperphosphatemia Drug in Japan
8. NexGenix Pharmaceuticals Enters into Exclusive World-wide License to Develop Novel Hsp90 Inhibitors
9. Elbit Medical Imaging Ltd. Announces that Plaza Centers Has Entered into a Joint Venture Partnership to Develop Residential and Office Projects in Romania
10. Sangui Partnership Enters a New Phase:
11. Nastech Enters Into Feasibility Study to Develop a Non-Injectable Dosage Form of Factor IX to Control Bleeding
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/8/2016)... OXFORD, England , December 8, 2016 /PRNewswire/ ... (OGT), das Unternehmen für Molekulargenetik, erweitert seine Palette ... SureSeq myPanel™ NGS Custom FH Panels, das ein ... Hypercholesterinämie (FH) ermöglicht. Das Panel bietet eine Erkennung ... Number Variations (CNV) mit einem einzigen kleinen Panel ...
(Date:12/8/2016)... ... December 08, 2016 , ... KBioBox ... response to client demand KbioBox developed a sophisticated “3 click” gene dditing off ... accessible from KBioBox’s new website, https://www.kbiobox.com/ and powered by the ...
(Date:12/8/2016)... ... ... This CAST literature review and report looks at problems caused by the current ... in countries that are major global commodity exporters and importers, which show that asynchrony ... level presence (LLP) puts large volumes of trade worth billions of dollars at risk. ...
(Date:12/8/2016)... TAMPA, Fla. , Dec. 8, 2016 /PRNewswire/ ... biopharmaceutical company that discovers, develops and plans to ... today that its shares of common stock were approved ... stock will begin trading on the OTCQX, effective ... To qualify for the OTCQX market, companies must ...
Breaking Biology Technology:
(Date:11/29/2016)... 2016   Neurotechnology , a provider ... technologies, today released FingerCell 3.0, a software ... that run on low-power, low-memory microcontrollers. FingerCell ... than 128KB of memory, enabling it to ... limited on-board resources, such as: mobile phones, ...
(Date:11/22/2016)... 2016 According to the new market research report ... Vein, Signature, Voice), Multi-Factor), Component (Hardware and Software), Function (Contact and Non-contact), ... market is expected to grow from USD 10.74 Billion in 2015 to ... 2016 and 2022. Continue Reading ... ...
(Date:11/17/2016)... , Nov. 17, 2016 Global Market Watch: ... Biobanks (Disease-Based Banks, Population-Based Banks and Academics) market is to ... for Private Biobanks shows the highest Compounded Annual Growth Rate ... region during the analysis period 2014-2020. North ... of 9.95% followed by Europe at ...
Breaking Biology News(10 mins):